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Abstract The use of recombinant bovine somatotropin
(rbST) to enhance milk production is approved in several
countries, but it is prohibited in the European Union. Accord-
ing to EU legislation, it is necessary to confirm positive
screening results prior to enforcement. Although adequate
screening assays are available nowadays, development of liq-
uid chromatography tandem mass spectrometry (LC-MS/MS)
confirmatory methods to detect low levels of rbST is still a
challenge. Here, we present a novel approach using immuno-
affinity enrichment on monolithic micro-columns in combina-
tion with state-of-the-art ultra-high pressure LC-MS/MS
(UHPLC-MS/MS) detection. The developed approach en-
ables detection and confirmation of rbST in serum at a deci-
sion limit (CCα) concentration of 0.8 ng mL−1. Furthermore,
the method is easy to handle, robust and reproducible. We
successfully applied the confirmatory method to serum sam-
ples from rbST treated cows that were found suspect after
immunoassay-based screening. The use of rbSTcould be con-
firmed over 1 week after treatment, and the developed method
demonstrated the sensitivity needed for effective control.
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Introduction
Already in the 1930s, extracts of pituitary glands containing
endogenous bSTwere used to increase milk yield [1, 2]. Wide-
spread application, however, was limited; as for one adminis-
tration, multiple pituitaries of slaughtered bovines were re-
quired [1]. This changed in the 1980s when biotechnology
offered the opportunity to produce recombinant bovine somato-
tropin (rbST) [2], enabling unlimited production of the growth
hormone and therefore its use on a large scale. Currently, its use
for milk production enhancement in dairy cattle is licensed in
the USA and other countries, with no restriction to the residue
levels. In Europe, there is concern about the effects of rbST on
the well-being of the animals and consumers concern related to
elevated IGF-1 hormone levels in milk. Because of this, rbST
use is banned in Europe [3]. The ban requires methods to detect
rbSTabuse, and several analytical strategies have been reported
[4]. Development of methods to detect rbST abuse is a major
challenge due to: (i) the low concentrations in blood, (ii) its
sequence similarity with the endogenous hormone bST (only
differing in the N-terminal amino acid) and (iii) the strong fluc-
tuations of levels of bST in serum [5, 6]. For these reasons,
adequate screening methods aiming at rbST itself, at relevant
levels, have failed to be developed so far. Recently, a polyclonal
antibody highly selective for rbSTwas produced and used in an
ELISA format [7]. This assay, however, still lacks the required
sensitivity to detect rbST in serum at relevant levels by factors
of 10 to 100. To overcome the problems in detecting rbST
directly, indirect screening methods focussed on detection of
rbST-related biomarkers instead of rbST itself [8, 9]. A multi-
plex screening approach developed by Ludwig et al. [8] pro-
vided a serum biomarker profile which correctly predicted rbST
use in 95 % of treated dairy cows. The number of true positives
met the detection capability (CCβ) requirements of Commis-
sion Decision 2002/657 [8, 10]. According to this decision, for
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positive findings (i.e. suspect samples) of a forbidden substance
in a screening assay, additional instrumental analysis is needed
to confirm its identity. Subsequent confirmation of forbidden
substances, like rbST, can be accomplished by targeted LC-MS/
MS analysis [11]. So far, only one confirmatory method for
rbST in serum of dairy cows has been described in literature
[5]. This method was able to detect rbST in cow serum at
concentrations from 4 to 10 ng mL−1 during a detection win-
dow from 4.5 h to 4 days after treatment [5]. However, the
method requires a large serum volume of 4mL and an extensive
sample preparation for cleanup [5]. Furthermore, detection of
rbST until 4 days after administration is not sufficient to be able
to detect the use of slow-releasing rbST formulas applied only
biweekly, according to treatment schedules [12]. Several stud-
ies showed that overall bST serum levels (i.e. bST and rbST
combined) after rbST treatment in dairy cows range from 1.5 to
45 ng mL−1 [6, 13–15]. Consequently, to enable detection of
rbST during both the (biweekly) treatment period and the peri-
od after treatment, detection methods need sensitivity at/or be-
low 1.5 ng mL−1. To achieve this sensitivity, selective purifica-
tion by use of antibodies against rbST is a promising approach.
The use of immuno-affinity purification methods have been
shown to be very effective for the detection of clinical important
proteins in serum [16]. Therefore, it is expected that application
of this approach to rbST will offer the sensitivity needed. In
general, anti-rbST antibodies need to be coupled to a carrier,
after which enrichment of the low abundant rbST from the
complex, protein-rich, serum background can be accomplished.
Monolith micro-columns are a promising carrier for the anti-
body because of their low nonspecific binding, in comparison
with beads and the intensive contact between the analyte and
the antibodies, as shown in literature for IGF-1 enrichment [17].
For rbST in serum samples, selective and sensitive enrichment
with monolith micro-columns may be promising as well. After
enrichment of rbST from the serum samples, tryptic digestion
was applied. The main advantage of tryptic digestion is the
improved sensitivity of the peptides in comparison with detec-
tion of the whole protein. In this study, we present the develop-
ment of a sensitive confirmatory method for rbST in serum of
dairy cattle (Fig. 1). Performance characteristics were deter-
mined in a preliminary in house validation. Applicability is
demonstrated by confirmation of rbST at relevant concentra-
tions in serum samples from rbST treated cows.
Experimental
Materials
Monsanto rbST standard was obtained from the National Hor-
mone & Peptide Program (NHPP) of Dr. Parlow (Torrance,
CA). Elanco rbST was obtained from Elanco (Indianapolis,
IN, USA). Lactotropin 500 mg single-dose syringes were pur-
chased from Centro de Tecnologia (Rio de Janeiro, Brazil).
Pierce BCA protein assay, the Finnpipette™ Novus i Mul-
tichannel Electronic and monolithic micro-columns (MSIA dis-
posable automation research tips (D.A.R.T.), containing ap-
proximately 10 mg packed bed Protein A or Protein A/G) were
all purchased from Thermo Fisher Scientific (Rockford, Illi-
nois). Ammonium sulphate, hydrochloric acid, potassium phos-
phate, sodium hydroxide, sodium phosphate and the ultrasonic
cleaner were purchased from VWR International (Amsterdam,
The Netherlands). Trypsin, tris(hydroxymethyl)aminomethane,
iodoacetamide (IAA), dimethyl sulfoxide (DMSO) and DL-di-
thiothreitol were purchased from Sigma-Aldrich Chemie
(Zwijndrecht, The Netherlands). Methanol and acetonitrile
were purchased f rom Bioso lve (Va lkenswaard ,
The Netherlands). Formic acid was purchased from Actu-All
chemicals (Oss, The Netherlands). Protein Lobind Tubes
(1.5 mL, 2.0 mL) and a table centrifuge model 5810R were
obtained from Eppendorf (Hamburg, Germany). The Jouan
GR 20-22 ultracentrifuge was obtained from Jouan (Saint-
Herblain, France). The Snijder test tube rotator was purchased
from Omnilabo International (Breda, The Netherlands). An
isotopic-labelled bST peptide AFPAMSLSGLFANAVLR and
a synthetic analogue of the rbST peptide MFPA
MSLSGLFANAVLRwere obtained fromBachem (Bubendorf,
Switserland). The LC-column: Kinetex 50×2.10 mm I.D.
1.3μmC18 (100Å) was purchased from Phenomenex (Utrecht,
the Netherlands). Bond Elut Plexa 30mg solid-phase extraction
columns were purchased from Agilent Technologies
(Amstelveen, The Netherlands). A Zymark TurboVap was pur-
chased from Biotage (Upsala, Sweden).
Serum samples
Serum samples from two controlled animal treatment studies
were used. In the first animal treatment study, serum samples
were obtained from one 3-year-old dairy cow (a) treated twice
with subcutaneous injections of 500 mg Lactotropin. This
treatment was part of a sequential Lactotropin-steroid treat-
ment schedule existing of three compounds in total. Of each
compound, two subcutaneous injections were administered
with 1 week interval. After each treatment, an adaptation pe-
riod of 2 weeks was taken into account. Blood samples were
collected daily during the week after each treatment. The sec-
ond animal treatment study was according to commonly used
rbST treatment conditions as recommended by the manufac-
turer: An adaptation period of 2 weeks was taken into account,
and then the cow was treated every second week with 500 mg
rbST, according to manufacturers’ guidelines. Serum samples
were obtained from one 3-year-old dairy cow (b).
After blood collection, the blood sample was placed at
room temperature for 4 h to coagulate. After coagulation, the
samples were centrifuged for 10 min at 3000×g, and serum
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was collected and stored at −20 °C until further use. The
experimental procedure was authorized by the ethical commit-
tee of ID-DLO in Lelystad, the Netherlands.
Preparation of polyclonal antiserum
The preparation of polyclonal antiserum against Elanco rbST
was described before by Heutmekers et al. [18]. Briefly, a
New Zealand White rabbit (no. 58) was immunized with
Elanco rbST at the Centre for Small Laboratory Animals in
Wageningen, the Netherlands. Blood was obtained at various
moments during the entire treatment period and serum was
collected. The sera collected over the total treatment were
pooled and stored at −80 °C for further use.
Ammonium–sulphate purification of polyclonal
antiserum
To concentrate the antibodies from the antiserum and to re-
move abundant proteins, first, the combined rabbit antiserum
no. 58 was diluted three times with PBS (154 mM NaCl,
5.39 mMNa2HPO4, 1.29 mMKH2PO4, pH 7.4). Then, slow-
ly, under constant stirring, an equal amount of saturated am-
monium sulphate was added. Next, this solution was left at
Fig. 1 Workflow for serum
preparation, enrichment with
monolith micro-columns and LC-
MS/MS measurement of rbST.
SPE solid phase extraction, pb
phosphate buffer, RT room
temperature, FA formic acid, ACN
acetonitrile
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room temperature for 30 min without stirring. Subsequently,
the solution was ultra-centrifuged for 10 min at 10,000×g, the
supernatant was discarded and the pellet was re-suspended in
PBS to restore the starting serum volume. Finally, the re-
suspended pellet was dialyzed against PBS for 24 h. The pro-
tein concentration was 6.6 mg mL−1 determined by the BCA
protein assay according to the manufacturer’s protocol.
Immobilization of purified antibodies on protein A
and protein A/G monolithic micro-columns followed
by rbST enrichment
Polyclonal anti-rbST ammonium–sulphate purified antibodies
were immobilized to monolithic micro-columns loaded with,
respectively, protein A or protein A/G by affinity binding. The
pipet tips containing the protein A and protein A/Gmonolithic
tichannel, which is an automated device having a repetitive
cycling function. First, the monolithic micro-columns were
washed ten times with 150 μL 20 mM phosphate buffer pH
7. Adherent solution was removed from the column by air
pressure. Next, 75 μL 0.1 mg mL−1 of the ammonium–sul-
phate-precipitated polyclonal anti-rbSTantibodies, resuspend-
ed in 20 mM phosphate buffer pH 7, was transferred over the
column 1000 times. After the last cycle, adherent solution was
removed from the column by air pressure. To remove un-
bound antibodies, the monolithic micro-columnswere washed
twice by 10 cycles of 150 μL 20mMphosphate buffer pH 7. It
took 50 min to obtain these freshly prepared monolith micro-
columns immobilized with ammonium–sulphate-precipitated
polyclonal anti-rbST antibodies, which were directly used for
rbST enrichment.
For immuno-enrichment, 1 mL serum sample or spiked se-
rum was diluted with 1 mL 20 mM phosphate buffer pH 7. The
sample was transferred 2000 times (300 μL per cycle) through
the anti-rbST-immobilized monolithic micro-column. The ad-
herent sample was removed from the column by air pressure.
To remove the remaining unbound sample, the monolithic
micro-columns were washed ten times with 150-μL portions
of 20-mM phosphate buffer. The captured rbSTwas then eluted
from the monolith micro-column by 50 μL 200 mM NaOH
(20 μL per cycle, 150 times). The eluate was collected, and
50 μL 50 mM Tris pH 7.9 was added before further use (final
pH>10). Eluates were stored at −20 °C until tryptic digestion.
The enrichment procedure took 4.5 h.
Digestion and cleanup of the immuno-affinity-purified
extract
For digestion of the proteins with trypsin, the pH of the obtained
solution was adjusted to 8–8.5 with 1 M HCl. After addition of
5 μL 45 mM DL-dithiothreitol (DTT), to reduce sulphur brid-
ges, the solution was mixed and incubated for 30 min at 37 °C.
The solution was cooled down to room temperature, and 5 μL
0.1 M iodoacetamide was added for methylation of the cyste-
ine residues. The solution was mixed on a vortex and incubat-
ed for 30 min at room temperature in the dark. For protein
digestion, 5 μg trypsin in 1 mM HCl (pH<3) was added,
followed by 20 μL acetonitrile, mixed by vortex and incubat-
ed 1 h at 37 °C. Digestion was stopped by the addition of
0.9 mL 5 % formic acid. Then, an internal standard solution
containing isotope-labelled bST peptide was added. This pep-
tide is a replicate of the 17 amino acids of the N-terminal end
of endogenous bST (AFPAMSLSGLFANAVLR) and only
differs in the N-terminal amino acid from the rbST incorpora-
tion of alanine–13C6
15N4, resulting in a total mass increase of
10 Da. The digest was concentrated on an Agilent Bond Elut
Plexa SPE column (60 mg): After conditioning the column
with 1 mL methanol and 1 mL 5 % formic acid in water, the
sample was applied onto the column. Then, the column was
washed with 1 mL 10 % acetonitrile and the sample was
eluted with 0.5 mL water/acetonitrile/formic acid (25:70:5,
v/v/v). The eluate was collected in 50 μL DMSO and evapo-
rated to approximately 60 μL on a TurboVap at 55 °C under
10 psi N2. Please note that the exact volume is not critical due
to the use of an internal standard. After cooling to room tem-
perature, 25 μL 5 % formic acid was added. The sample was
mixed and transferred to an LC injection vial. The digestion
and concentration procedure took in total 3 h.
LC-MS/MS analysis
Analysis was performed using an I-Class UPLC system con-
nected to a Xevo TQS mass spectrometer Waters (Manchester,
UK). Thirty microliters from the final extract was analysed by
UHPLC-MS/MS in multiple reaction monitoring (MRM)
mode. The chromatographic separation was performed on a
Kinetex 50×2.10 mm I.D. 1.3 μm C18 (100 Å) column. The
flow rate was set at 0.5 mL min−1. A gradient was used starting
with 75:25 (v/v) water/acetonitrile for the first 30 s, increasing to
70:30 (v/v) water/acetonitrile in the next 3 min. Then, the col-
umnwaswashed for half aminutewith 100% acetonitrile. Total
run timewas 6min 30 s. Themass spectrometer was operated in
the positive ion ESI-MS/MS mode. Ion transitions m/z 913.1>
774.1 and m/z 913.1>1047.6 were measured to detect the rbST
specific N-terminal peptide with amino acid sequence, MFPA
MSLSGLFANAVLR, after tryptic digestion [19]. To check the
retention time of this N-terminal rbST peptide of interest, a
synthetic analogue of the rbST peptide was injected at the be-
ginning and the end of each series. For the bST internal stan-
dard, the transition m/z 888.1>779.13 was followed.
In-house method validation
The decision limit CCα and the detection capability CCβ
were determined according to the calibration procedure
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micro-columns were placed on the Finnpipette® Novus i mul-
conform Commission Decision 2002/657/EC. Calculation of
the concentration was performed by constructing a linear cal-
ibration curve of the response factor (peak area ratio of rbST
fragment and internal standard) vs the concentration
(expressed as absolute amount rbST protein). For intra-assay
variation, four identical rbST spiked serum samples of respec-
tively 2 and 10 ng mL−1 rbST in serum were analysed in
parallel. Variation was determined and expressed as the per-
centage of the average. For determination of inter-assay vari-
ation, the spiked serum samples of 2 and 10 ng mL−1 were
prepared, enriched with monolith micro-columns and mea-
sured on three different days. Variation was determined and
expressed as the percentage of the average. For recovery of the
immuno-affinity isolation, rbST-spiked serum samples were
analysed and compared to rbST calibration curve in sodium
hydroxide, as the latter is compatible with the elution condi-
tions after immune-affinity rbST enrichment.
Results and discussion
Optimization rbST immuno-affinity enrichment
For the enrichment of the low abundant rbST from serum of
dairy cattle (Fig. 1), two monolith micro-columns were com-
pared: a monolith micro-column prepared with protein A and
a monolith micro-column prepared with protein A/G. Both
protein A and protein A/G have a high affinity for polyclonal
rabbit antibodies [17] and are expected to strongly interact
with the rabbit anti-rbST used in this study. After rabbit anti-
rbST immobilization on both monolith micro-columns, the
protein A monolith micro-column was able to capture 10–
20 % more rbST from spiked serum samples compared with
the protein A/G monolith micro-column. Therefore, the pro-
tein A monolith micro-column was used for further optimiza-
tion steps.
To obtain the highest recovery of rbST, the number of pi-
petting cycles, pipetting speed, antibody immobilization con-
centration and elution conditions were investigated with
spiked serum samples. The number of pipetting cycles was
determined to be 2000, taking both the efficiency of enrich-
ment and time into consideration. The pipetting speed was
found to be of great importance for both immobilization of
the antibody on the monolith micro-column and for rbST cap-
ture from serum samples. To effectively immobilize the poly-
clonal anti-rbST antibody onto the monolith micro-column,
the solution had to be transferred through the column with
slowest pipetting rate as practically possible (approximately
63μL s−1). Otherwise, immobilization of the antibodywas not
sufficient and no rbST was captured. The same result was
obtained for the transfer of serum samples over the monolith
micro-column to enable rbST capture: rbST could only be
detected when the serum was transferred slowly through the
micro-column (approximately 77 μL s−1).
Next, the concentration of anti-rbST antibody used for im-
mobilization to the monolith micro-columns was optimized,
aiming for the highest yield of rbSTafter enrichment. For this,
anti-rbST was applied to the column with concentrations of
0.1, 0.07, 0.04 and 0.01 mg mL−1 in 20 mM phosphate buffer
pH 7. The immobilization concentration of 0.1 mg mL−1
showed best rbST capture capacity respectively 2, 3 and 7
times more rbST was captured using 0.1 mg mL−1 compared
with the other concentrations. Higher concentrations of the
antibody were not tested as immobilization with
0.1 mg mL−1 antibody was capable to enrich rbST in serum
at concentrations in the low nanogram per milliliter range,
sensitive enough for incurred serum samples. The binding
sites of the micro-columns prepared under these conditions
were found to be saturated at a serum rbST concentration of
>50 ng mL−1, which is at least 50 times higher than the ex-
pected levels of rbST in treated cows (Fig. 2).
For the elution of captured rbST, conditions compatible
with the subsequent trypsin digestion are preferred to simplify
the workflow. Trypsin digestion compatible buffers are for
instance tris and ammonium bicarbonate. These buffers were
tested in different molarities for their capacity to elute rbST
from the monolith micro-columns. Unfortunately, these con-
ditions are too mild, only eluting 10 % or less rbST from the
monolith micro-columns in comparison with harsher elution
conditions. A solution of 200 mM NaOH was found to be
most effective for elution of rbST from the micro-columns.
After elution, a tris solution was added to obtain a trypsin
compatible solution. In Fig. 1, an overview of the entire
workflow developed is given. In short, after enrichment of
rbST with monolith micro-columns from serum supernatant,
tryptic digestion yields 20 different peptides. The endogenous
and recombinant protein differs by one amino acid located at
the N-terminal side of the protein. In case of rbST, an alanine
is replaced by a methionine. To discriminate between these











Fig. 2 Peak areas obtained with LC-MS/MS transition m/z 913.1>m/z
774.13 after enrichment of rbST in spiked serum samples at: 0, 2, 4, 6, 8,
10, 50 and 100 ngmL−1. The observation of a plateau beyond 50 ngmL−1
indicates saturation of the binding sites of the micro-columns
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two forms, the N-terminal peptide is analysed. To be sure that
the detected N-terminal peptide is specific, a blast computa-
tion was performed at the SIB using the BLAST network
service [20]. There were no other peptides found containing
the same amino acid sequence as the detected peptide. The
addition of the isotope-labelled N-terminal peptide of bST as
an internal standard allows to correct for sample cleanup
losses after tryptic digestion.
Method performance characterization
To characterize the method performance, the developed
method was partly validated in-house as a quantitative
confirmatory method according to Commission Decision
2002/657/EC [10]. The parameters considered were the
decision limit (CCα), the detection capability (CCβ),
the intra-assay variation, the inter-assay variation and
the recovery. Ion ratio of the measured transition deter-
mined for samples from the matrix matched sample
(MMS) series and samples from rbST-treated animals
were all within the ion ratio limits, as described in the
Commission Decision 2002/657/EC [10].
Important parameters for performance characterization are
(i) the decision limit (CCα), the limit at and above which it can
be concluded, with an error probability of α, that a sample is
non-compliant; (ii) the detection capability (CCβ), the
smallest content of the substance that may be detected, iden-
tified and quantified in a sample with an error probability ofβ;
(iii) the intra-assay variation; (iv) the inter-assay variation; and
(v) the recovery. In the case of substances for which no per-
mitted limit has been established, the detection capability is
the lowest concentration at which a method is able to truly
detect contaminated samples with a statistical certainty of 1
−β.
Data obtained from the validation study are presented in
Table 1. The CCα and CCβ were determined to be 0.8 and
1.6 ng mL−1, respectively. From additional samples spiked
with rbST in concentrations of 0.25, 0.5 and 1 ng mL−1, it
was concluded that the obtained CCα and CCβ are realistic,
as the 0.5 and 1 ng mL−1 samples still meet the ion ratio
criteria (see also the reconstructed ion chromatogram of the
rbST-spiked serum sample at 1 ng mL−1 in Fig. 3). Moreover,
in 75% of blank serum samples spiked at CCα (0.8 ng mL−1),
rbST presencewas confirmed, which is actually better than the
>50 % at CCα level as required by 2002/657/EC.
Intra- and inter-assay variations were determined for
rbST in serum at a concentration of 2 and 10 ng mL−1,
in accordance with expected serum concentrations. Varia-
tion was expected to be higher at 2 ng mL−1 compared
with 10 ng mL−1. Although this difference was indeed
observed in both intra- and inter-assay variation, intra-
assay variation was found to be only 12 % at 2 ng mL−1
and 9 % at 10 ng mL−1 rbST in serum (Table 1). It should
be noted that for 10 ng mL−1, one of the four data points
was removed as outlier due to the fact that the internal
standard was not added correctly.
Recovery was determined by comparison of calibration
curves prepared in either elution solvent or by fortification
of serum. The graphs in Fig. 4 shows that not all rbST from
the fortified serum samples will be captured and eluted using
the monolith micro-columns. Comparison of the response fac-
tors of the two calibration curves suggests a recovery during
immuno-enrichment of approximately 50 % for concentra-
tions up to 10 ng mL−1. For the two highest concentrations,
50 and 100 ng mL−1, the recovery of rbST dropped to 25 and
17 %, respectively, due to saturation of the binding sites of the
monolith micro-column (Fig. 2). Even though not all rbST is
recovered, the repeatability and reproducibility data in Table 1
are fit for purpose and the sensitivity required for effective
control is reached.
To test the stability of the trypsin-digested serum, samples
were stored for 2 weeks at 4–8 °C. Comparison of the samples
before and after storage showed a decrease in peak area of
approximately 50 % for all samples (results not shown). The
decrease in intensity of the measured N-terminal peptide can
be explained by its instability and tendency to adsorb to glass-
ware [21]. Although 50 % is a significant loss at 4–8 °C, it did
not obstruct measurement and quantification of rbST in the
extracts. It is therefore advised to store digested samples and
matrix-matched calibrants at 4–8 °C as short as possible prior
to analysis.
Detection of rbST in bovine serum has already been pre-
sented before by Le Breton et al. [5]. In that work, the
lowest presented rbST concentration in bovine serum was
3 ng mL−1 (data acquired on only one transition). To reach
that level, an extensive sample preparation of multiple pre-
cipitation steps and overnight digestion was needed. In con-
trast, the method presented in this study shows high sensi-
tivity (CCα of 0.8 ng mL−1) and the confidence of data
acquisition of two ion transitions. Note that using a
single-ion transition, rbST in bovine serum with a concen-
tration of 0.25 ng mL−1 could even be detected. Moreover,
Table 1 In-house validation study to characterize the method
performance using monolith micro-columns loaded with protein A, tryp-
tic digestion and LC-MS/MS analyses
Validation results
CCα 0.8 ng mL−1
CCβ 1.6 ng mL−1
Intra-assay variation 2 ng mL−1 12 % (n=4)
10 ng mL−1 9 % (n=3)
Inter-assay variation 2 ng mL−1 15 % (n=3)
10 ng mL−1 10 % (n=3)
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sample preparation is less extensive, less laborious and
semi-automated, and tryptic digestion required only 1 h.
rbST analysis in serum of rbST-treated cows
To investigate applicability of the developed method to real-
life samples, serum samples from two different animal exper-
iments were analysed. As a proof of principle, from the first
animal experiment, 17 serum samples of one treated cow were
analysed: two serum samples prior to treatment (t=<0 days),
one serum sample for each day after the first and second treat-
ment (t=1–14 days) and one sample 3 weeks after the second
treatment (t=29 days). This allowed exploring the detectabil-
ity of rbST during and after the treatment period. Obtained
rbST concentrations, corrected for incomplete recovery, are
given in Table 2 and show that rbST can be detected from
the first day after the first treatment until 7 days after the
second treatment. Only in one serum sample, taken on day
2, no rbST seemed to be present. It is not clear why no rbST
was detected in the sample that day. The highest concentration
of rbST (21.4 ng mL−1) was detected on the first day after the
Fig. 3 A Top bar shows the results of the screenings analysis, B LC-MS/
MS confirmation of biomarker screening results. Chromatograms of
transition m/z 913.1>m/z 774.13 and m/z 913.1>m/z 1047.6 after
enrichment of rbST in serum in (from left to right): a serum sample
prior to treatment (day 0), a serum sample taken the first day of
treatment (determined to contain 9.0 ng mL−1 rbST), a serum sample
taken 7 days after treatment (determined to contain 1.9 ng mL−1 rbST),
a serum sample taken 14 days after treatment (determined to contain<
1 ng mL−1) and a serum sample spiked with 1 ng mL−1 rbST. All y-axes
are scaled to the serum sample of the first day of treatment. Below the
chromatogram, the compliance with the ion ratio and retention time
criteria is indicated (the ion ratio and retention time interval as
determined according to the 2002/657/EC are given in brackets)
















Fig. 4 Calibration curves with respectively 0, 2, 4, 6, 8 and 10 ng mL−1
of rbST spiked in NaOH (black circle) to simulate enrichment elution
conditions and after immuno-affinity enrichment of fortified serum sam-
ples (black square)
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first treatment. On the first day after the second treatment, an
increase in rbSTwas observed as well, although less apparent.
In general, a daily variation in rbST concentration was ob-
served and rbST concentrations decreased only slowly. This
suggests the ability of the slow-releasing formulae to release
rbST slowly to the blood circulation, with a peak on the first
day(s), and maintain a minimum level. Twenty-one days after
the last treatment, no rbST could be detected anymore, which
is in good agreement with the need of a two-weekly treatment,
as advised by the manufacturer [12]. This treatment schedule
was applied in the second animal study. Analysis of samples
from this study gives insight in the ability of the method to
detect rbST use under realistic treatment conditions. Four se-
rum samples were analysed: one serum sample prior to treat-
ment (t=<0 days) and serum samples taken after 1 day (t=
1 day), 1 week (t=8 days) and 2 weeks (t=14 days) after the
third treatment. In addition, three additional blank serum sam-
ples from other animals were analysed.
No rbST was detected in any of the five blank serum sam-
ples, and no interferences are observed that could lead to false-
positive findings. This implies that the method is very specific,
though analysis of more non-treated animals is needed to sta-
tistically prove these findings. From the treated cow (b), the
trend of the determined rbST concentrations is similar to the
first animal experiment. The highest concentration was found
on the first day after administration, and rbSTcould be detect-
ed until 1 week after administration (see Table 2 and Fig. 3).
The difference in concentration on the first day after treatment
between the two cows from the two animal experiments can
be explained by natural variation in response, which should be
investigated by analysis of more treated animals. For the se-
rum sample taken 2 weeks after rbSTadministration, just prior
to the following administration, a peak is clearly visible at
transition m/z 993.1>m/z 774.13 and suggests the presence
of rbST (Fig. 3). However, the concentration is lower than
the CCα of the method, and for confirmation of rbST accord-
ing to Commission Decision 2002/657/EC, a concentration
larger than CCα and a peak at a second transition are neces-
sary. Further enhancement of the sensitivity may be obtained
by increasing the sample volume. It is expected that by this
Table 2 RbST concentrations found in serum samples of two dairy cows, a and b treated with rbST, quantified versus MMS
Syringes (left side for cow a; right side for cow b) show days of treatment with rbST in slow releasing formulae
B–^ not determined
6048 N.G.E. Smits et al.
adjustment, rbST presence can not only be detected but also
confirmed up to 14 days after rbSTadministration. The results
compare favourably with previousmethods [5], in which rbST
was only detected until 4 days after treatment.
Confirmation of positive screening results
Control strategies in food and feed safety often include
two steps: First, samples are screened in order to obtain
a fast indication of the suspect samples, thereby reducing
the number of samples, as samples with a negative result
will not be investigated further. The second step in the
control strategy is the confirmation of positive samples
conform Commission Decision 2002/657 with additional
(analytical) methods [10]. This two-step strategy was ap-
plied to the four samples from the second animal study.
The samples were previously screened by Ludwig et al.
[8] by a multiple protein biomarker assay, where four
different biomarker proteins were measured simultaneous-
ly. The serum samples were selected for analysis with the
LC-MS/MS method as they were considered suspicious
for rbST in the screening assay (Fig. 3a). The sample
taken prior to treatment (t=<0 days) was screened sus-
pect, which is obviously unlikely and might serve as a
false-positive case. Analysis of the serum sample prior
to treatment (t=<0 days) with our confirmatory method
showed that, indeed, despite the positive screening result,
no rbST-specific peptide could be detected and rbST was
below our detection limit (Fig. 3b). It can therefore be
concluded that the screening result of this sample, taken
before treatment, is false positive and underlines the ne-
cessity of confirmatory methods. The false-positive
screening result was most likely due to the apparent pres-
ence of rbST-induced antibodies as was observed in less
than 5 % of the untreated cows and is most likely the
result of non-specific interactions of other antibodies or
proteins in the screening assay [22].
For the other three serum samples, taken during rbST treat-
ment according to the treatment schedule, screening results
were found to be true positive. As shown in Fig. 3b by the
chromatograms of transition m/z 913.1>m/z 774.13 and m/z
913.1>m/z 1047.6, samples taken during the rbST treatment
all showed rbST presence.
Samples taken after treatment of dairy cows with rbST (t-
=>0 days), which were found positive in the screenings assay,
were confirmed for the presence of rbST with the developed
confirmatory LC-MS/MS method (Fig. 3). In addition, the
need of a reliable confirmatory method for samples found
positive during screening was proven by the example of a
false-positive screening result that could only be identified
by the LC-MS/MS analysis. Please note that no explicit con-
firmation criteria have been established yet for protein and/or
peptide analysis by targeted MS/MS.
Conclusion
In this study, a novel approach to pinpoint rbST abuse has
been developed based on rbST enrichment by immuno-
affinity on monolith micro-columns. High sensitivity is
reached with a CCα of 0.8 ng mL−1. The intra- and inter-
assay variations were determined to be <10 % at
10 ng mL−1 and <18 % at 2 ng mL−1. Applicability of the
confirmatory method was demonstrated by analysis of serum
samples from a treated animal for which positive screening
results were obtained. With the developed approach, we quan-
tify rbSTwith a detection window of the total treatment period
of 14 days and confirm its presence for over 1 week after
treatment. It is therefore that, for the first time, to the best of
our knowledge, an approach is presented that successfully
proofs rbST abuse under commonly used treatment
conditions.
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